Open AccessOutcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
Author(s) -
Tyler Berger,
Matthew W. Manry,
Lucas Lindsell,
James M. Osher,
Daniel M. Miller,
Robert E. Foster,
Christopher D. Riemann,
Michael R. Petersen,
Robert A. Sisk
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s294789
Subject(s) - medicine , macular telangiectasia , ophthalmology , visual acuity , macular degeneration , optical coherence tomography , fluorescein angiography
To evaluate if off-label Age-Related Eye Disease Study 2 (AREDS2) supplementation prevents visual and anatomical deterioration in non-proliferative Idiopathic Macular Telangiectasia Type 2 (IMT2).